Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'

F H van Bruggen, G B J Nijhuis, S U Zuidema, H J Luijendijk*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

Originele taal-2English
Aantal pagina's2
TijdschriftExpert Review of Clinical Pharmacology
Vroegere onlinedatum11-jan-2021
DOI's
StatusPublished - 21-jan-2021

Citeer dit